Detailed Explanation
The New Drug Application represents the culmination of years of drug development, presenting the complete body of evidence demonstrating that a new drug is safe and effective for its proposed use. This submission marks the formal request to FDA for permission to market the drug product in the United States. The NDA consolidates all data from preclinical studies, clinical trials, manufacturing process development, and labeling into a comprehensive package that regulatory reviewers evaluate to make an approval decision.
The NDA contains multiple sections organized according to the Common Technical Document format, which has been internationally harmonized across major regulatory regions. Module 1 contains administrative information and prescribing information. Module 2 provides summaries of each technical section. Module 3 details chemistry, manufacturing, and controls. Module 4 presents nonclinical study reports. Module 5 contains clinical study reports and integrated analyses of safety and efficacy. This standardized structure facilitates global development programs and simultaneous submissions to multiple regulatory authorities.